Keyword: Frazier Healthcare
The series A positions the startup, Mavupharma, to further its work on the use of oral STING modulators to treat cancer and infectious diseases.
California investment firm Frazier Healthcare Partners has gone over its hard cap target of $400 million as it looks to inject cash into early life science work.
Iterum has completed a $65 million series B to equip it to take its antibiotic sulopenem through phase 3.
Frazier Healthcare Partners has once again installed a trio of biotech veterans at the helm and put up cash to get through a vital trial.
Alcresta has raised $49.4 million in a Series C financing to support the launch of its novel digestive enzyme cartridge Relizorb. Up first, it's aiming for the sub-set of cystic fibrosis patients who rely upon a feeding tube for nutrition.